| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double … JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ... The Lancet 399 (10326), 729-740, 2022 | 275 | 2022 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 250 | 2022 |
| Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial J Sahni, SS Patel, PU Dugel, AM Khanani, CD Jhaveri, CC Wykoff, ... Ophthalmology 126 (8), 1155-1170, 2019 | 224 | 2019 |
| Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial AM Khanani, SS Patel, PJ Ferrone, A Osborne, J Sahni, S Grzeschik, ... JAMA ophthalmology 138 (9), 964-972, 2020 | 132 | 2020 |
| Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration SJ Haug, DL Hien, G Uludag, TTT Ngoc, S Lajevardi, MS Halim, ... American journal of ophthalmology case reports 18, 100680, 2020 | 125 | 2020 |
| Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression PA Campochiaro, A Khanani, M Singer, S Patel, D Boyer, P Dugel, ... Ophthalmology 123 (8), 1722-1730, 2016 | 122 | 2016 |
| Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab M Khan, AA Aziz, NA Shafi, T Abbas, AM Khanani Cells 9 (8), 1869, 2020 | 102 | 2020 |
| Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations A Jain, S Chea, W Matsumiya, MS Halim, Ç Yaşar, G Kuang, YJ Sepah, ... American Journal of Ophthalmology Case Reports 18, 100687, 2020 | 97 | 2020 |
| Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map AM Khanani, MA Zarbin, MR Barakat, TA Albini, PK Kaiser, B Guruprasad, ... JAMA ophthalmology 140 (1), 20-28, 2022 | 84 | 2022 |
| SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States AM Khanani, A Skelly, V Bezlyak, R Griner, LR Torres, A Sagkriotis Ophthalmology Retina 4 (2), 122-133, 2020 | 76 | 2020 |
| Emerging therapies in neovascular age-related macular degeneration in 2020 A Samanta, AA Aziz, M Jhingan, SR Singh, AM Khanani, J Chhablani Asia-Pacific Journal of Ophthalmology 9 (3), 250-259, 2020 | 73 | 2020 |
| Review of gene therapies for age-related macular degeneration AM Khanani, MJ Thomas, AA Aziz, CY Weng, CJ Danzig, G Yiu, S Kiss, ... Eye 36 (2), 303-311, 2022 | 65 | 2022 |
| End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration AM Khanani, D Callanan, R Dreyer, S Chen, JG Howard, JJ Hopkins, ... Ophthalmology Retina 5 (8), 775-787, 2021 | 60 | 2021 |
| Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis S Kiss, PU Dugel, AM Khanani, MS Broder, E Chang, GH Sun, A Turpcu Clinical ophthalmology, 1625-1635, 2018 | 59 | 2018 |
| Day to day variability of the dark-adapted pupil diameter SM Brown, AM Khanani, KT Xu Journal of Cataract & Refractive Surgery 30 (3), 639-644, 2004 | 49 | 2004 |
| Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham … JS Heier, EM Lad, FG Holz, PJ Rosenfeld, RH Guymer, D Boyer, F Grossi, ... The Lancet 402 (10411), 1434-1448, 2023 | 48 | 2023 |
| Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial SS Patel, DR Lally, J Hsu, CC Wykoff, D Eichenbaum, JS Heier, GJ Jaffe, ... Eye 37 (17), 3551-3557, 2023 | 46* | 2023 |
| Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial AM Khanani, SS Patel, G Staurenghi, R Tadayoni, CJ Danzig, ... The Lancet 402 (10411), 1449-1458, 2023 | 45 | 2023 |
| Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial BD Kuppermann, M Goldstein, RK Maturi, A Pollack, M Singer, A Tufail, ... Ophthalmologica 234 (1), 40-54, 2015 | 43 | 2015 |
| Optimal management of pigment epithelial detachments in eyes with neovascular age-related macular degeneration AM Khanani, D Eichenbaum, PG Schlottmann, L Tuomi, D Sarraf Retina 38 (11), 2103-2117, 2018 | 42 | 2018 |
